| Reaction Details |
|---|
 | Report a problem with these data |
| Target | P2X purinoceptor 3 |
|---|
| Ligand | BDBM50580220 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_2147575 (CHEMBL5031921) |
|---|
| IC50 | 6.3±n/a nM |
|---|
| Citation |  Kai, H; Horiguchi, T; Kameyma, T; Onodera, N; Itoh, N; Fujii, Y; Ichihashi, Y; Hirai, K; Shintani, T; Nakamura, K; Minami, K; Kasai, E; Yoneda, S; Murakami, Y; Ogawa, H; Sekimoto, R; Shinohara, S; Yoshida, O; Kurose, N Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists. Bioorg Med Chem Lett52:0 (2021) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| P2X purinoceptor 3 |
|---|
| Name: | P2X purinoceptor 3 |
|---|
| Synonyms: | ATP receptor | Glucocorticoid receptor | P2RX3 | P2RX3_HUMAN | P2X purinoceptor 3 | P2X purinoceptor 3 (P2RX3) | P2X purinoceptor 3 (P2X3) | P2X3 | P2X3 purinoceptor | Purinergic receptor | p2x3 + hsa |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 44292.02 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P56373 |
|---|
| Residue: | 397 |
|---|
| Sequence: | MNCISDFFTYETTKSVVVKSWTIGIINRVVQLLIISYFVGWVFLHEKAYQVRDTAIESSV
VTKVKGSGLYANRVMDVSDYVTPPQGTSVFVIITKMIVTENQMQGFCPESEEKYRCVSDS
QCGPERLPGGGILTGRCVNYSSVLRTCEIQGWCPTEVDTVETPIMMEAENFTIFIKNSIR
FPLFNFEKGNLLPNLTARDMKTCRFHPDKDPFCPILRVGDVVKFAGQDFAKLARTGGVLG
IKIGWVCDLDKAWDQCIPKYSFTRLDSVSEKSSVSPGYNFRFAKYYKMENGSEYRTLLKA
FGIRFDVLVYGNAGKFNIIPTIISSVAAFTSVGVGTVLCDIILLNFLKGADQYKAKKFEE
VNETTLKIAALTNPVYPSDQTTAEKQSTDSGAFSIGH
|
|
|
|---|
| BDBM50580220 |
|---|
| n/a |
|---|
| Name | BDBM50580220 |
|---|
| Synonyms: | CHEMBL5086991 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C23H20ClN5O5S |
|---|
| Mol. Mass. | 513.953 |
|---|
| SMILES | C[C@@H](Cn1c(=O)[nH]\c(=N/c2ccc(Oc3nccs3)cc2)n(Cc2ccc(Cl)cc2)c1=O)C(O)=O |r| |
|---|
| Structure | 
|
|---|
Search and Browse
